Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Hannah Wallace und 21 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of New South Wales, Eli Lilly Australia, Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2 inhibitors) and glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) have cardio‐kidney‐metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1‐RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care. Materials and Methods We conducted a retrospective, cohort study of adults with T2DM who attended primary care practices participating in MedicineInsight. The outcome of interest was the percentage of patients with CKD who received ≥1 prescription for an SGLT2 inhibitor or a GLP1‐RA (assessed separately) compared to those without CKD during 2020–2021. We also assessed prescriptions in a sub‐population of CKD patients who met trial inclusion criteria: SGLT2 inhibitor (estimated glomerular filtration rate [eGFR] ≥20 mL/min/1.73m 2 and urine albumin‐creatinine ratio [UACR] ≥22.6 mg/mmol) and GLP1‐RA (eGFR ≥50 to 33.9 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
- Western Health, Melbourne, Victoria, Australia.
- Faculty of Medicine and Health, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
- NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Hannah Wallace, Brendon L Neuen, Michael O Falster, Jialing Lin, Takaya Sasaki, Mark Woodward, Sradha S Kotwal, Min Jun
Förderung
- University of New South Wales
- Eli Lilly Australia
- Boehringer Ingelheim
Zitieren
APA
Wallace, H., Wick, J., Neuen, B. L., Buizen, L., Badve, S. V., Chalmers, J., de Oliveira Costa, J., Falster, M. O., Ha, J. T., Jardine, M. J., Ketema, D. B., Lin, J., Nelson, C., Pearson, S. A., Peiris, D., Rodgers, A., Sasaki, T., Woodward, M., Gallagher, M., …, & Jun, M. (2025). Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16608
Vancouver
Wallace H, Wick J, Neuen BL, Buizen L, Badve SV, Chalmers J, et al. Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16608
BibTeX
@article{Wallace2025,
author = {Wallace, Hannah and Wick, James and Neuen, Brendon L and Buizen, Luke and Badve, Sunil V and Chalmers, John and de Oliveira Costa, Juliana and Falster, Michael O and Ha, Jeffrey T and Jardine, Meg J and Ketema, Daniel Bekele and Lin, Jialing and Nelson, Craig and Pearson, Sallie-Anne and Peiris, David and Rodgers, Anthony and Sasaki, Takaya and Woodward, Mark and Gallagher, Martin and Kotwal, Sradha S and Ronksley, Paul and Jun, Min},
title = {Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16608}
}
EUVIMED